According to Larry Merizalde, China CEO of South African manufacturer Aspen, “we’ve seen some disturbance in our ability to implement some clinical application actions and in the ability of our health representatives to attend hospitals.”
AstraZeneca was likewise “facing challenges from the medical anti-corruption investigations in China, reducing AZN’s exposure to physicians in the region as well as having some bad effects on prescription volumes,” according to Barclays in a subsequent note.
As the company reports quarterly results later on Thursday ( Nov 9 ), a spokesperson for AstraZeneca declined to comment.
However, the two executives claimed that over the previous two months, after communications like a National Health Commission Q&, A, and an established display from the government, things had gotten better overall.
Since the government’s most recent announcements outlining the goals of this anti-corruption plan, we have observed that total activities have returned to normal over the past month, according to Merizalde.
China is one of the largest medical markets for international healthcare providers, but this year’s business climate has deteriorated as a result of factors like the anti-graft drive.